| scholarly article | Q13442814 |
| P50 | author | Alan I Reed | Q62015727 |
| P2093 | author name string | David R Nelson | |
| Chen Liu | |||
| Roberto J Firpi | |||
| Haizhen Zhu | |||
| Victor I Machicao | |||
| Consuelo Soldevila-Pico | |||
| Giuseppe Morelli | |||
| Roniel Cabrera | |||
| Manal F Abdelmalek | |||
| P2860 | cites work | Results of retransplantation for recurrent hepatitis C. | Q44675034 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatitis C | Q154869 |
| virology | Q7215 | ||
| liver transplantation | Q1368191 | ||
| cyclosporine | Q367700 | ||
| Hepatitis C virus | Q708693 | ||
| P304 | page(s) | 51-57 | |
| P577 | publication date | 2006-01-01 | |
| P1433 | published in | Liver Transplantation | Q15730498 |
| P1476 | title | Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation | |
| P478 | volume | 12 |
| Q33602527 | A comprehensive review of immunosuppression used for liver transplantation |
| Q54333493 | A cyclosporine-based immunosuppressive regimen may be better than tacrolimus for long-term liver allograft survival in recipients transplanted for hepatitis C. |
| Q33793057 | A delicate balance between rejection and BK polyomavirus associated nephropathy; A retrospective cohort study in renal transplant recipients |
| Q37630394 | Antiviral therapy of chronic hepatitis C in patients with advanced liver disease and after liver transplantation |
| Q42991460 | Antiviral treatment of patients with recurrent hepatitis C after liver transplantation with pegylated interferon |
| Q36750266 | Approach to recurrent hepatitis C following liver transplantation |
| Q37313166 | Avoiding therapeutic pitfalls: the rational use of specifically targeted agents against hepatitis C infection |
| Q35099077 | BK Virus in Kidney Transplant Recipients: The Influence of Immunosuppression |
| Q27011871 | Challenges of recurrent hepatitis C in the liver transplant patient |
| Q43037856 | Conversion to mycophenolate mofetil for modulating recurrent hepatitis C in liver transplant recipients |
| Q39870509 | Current status of organ transplantation in Japan and worldwide |
| Q42140198 | Cyclophilin and viruses: cyclophilin as a cofactor for viral infection and possible anti-viral target. |
| Q38615621 | Cyclophilin inhibitors as a novel HCV therapy |
| Q36916858 | Cyclophilin inhibitors in hepatitis C viral infection |
| Q28483731 | Cyclosporin A inhibits the influenza virus replication through cyclophilin A-dependent and -independent pathways |
| Q29619682 | Diagnosis, management, and treatment of hepatitis C: an update |
| Q38204468 | Directly acting antivirals (DAAs) for the treatment of chronic hepatitis C virus infection in liver transplant patients: "a flood of opportunity". |
| Q38061056 | Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms |
| Q38028429 | Efficacy of antiviral therapy for hepatitis C after liver transplantation with cyclosporine and tacrolimus: a systematic review and meta-analysis |
| Q37355472 | Evolving concepts in the selection of immunosuppression regimen for liver transplant recipients |
| Q42982631 | HCV in liver transplantation |
| Q37106320 | HSV keratitis: histopathologic predictors of corneal allograft complications |
| Q43001526 | Hepatitis C recurrence after liver transplantation: Viral and histologic response to full-dose PEG-interferon and ribavirin. |
| Q37313982 | Hepatitis C virus and inflammatory bowel disease |
| Q37972771 | Hepatitis C virus treatment pre- and post-liver transplantation. |
| Q45409094 | Histological benefit of retreatment by pegylated interferon alfa-2b and ribavirin in patients with recurrent hepatitis C virus infection posttransplantation |
| Q45364028 | Hot-topic debate on hepatitis C virus: the type of immunosuppression matters |
| Q38044761 | Immunomodulating options for liver transplant patients |
| Q43039673 | Impact of calcineurin inhibitors with or without interferon on hepatitis C virus titers in a chimeric mouse model of hepatitis C virus infection |
| Q50576126 | Impact of pegylated interferon alpha-2B and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: an open-label series. |
| Q43876782 | Intensive care treatment following transplant surgery |
| Q42925798 | Kidney Transplantation in HIV-Infected Recipients: Encouraging Outcomes, but Registry Data Are No Longer Enough |
| Q58796111 | Kisspeptin/GPR54 signaling restricts antiviral innate immune response through regulating calcineurin phosphatase activity |
| Q58704499 | Liver transplantation and hepatitis C |
| Q38737314 | Maintenance immunosuppression for adults undergoing liver transplantation: a network meta-analysis. |
| Q36788362 | Management of hepatitis C infection after liver transplantation |
| Q34298333 | Management of recurrent hepatitis C following liver transplantation |
| Q39736462 | Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors |
| Q27489369 | Mutations in the hepatitis C virus polymerase that increase RNA binding can confer resistance to cyclosporine A |
| Q34093754 | Natural history, treatment and prevention of hepatitis C recurrence after liver transplantation: past, present and future |
| Q52561132 | Novel activities of safe-in-human broad-spectrum antiviral agents. |
| Q43041850 | Of mice and men, calcineurin inhibitors and hepatitis C. |
| Q30432292 | Outcomes of Kidney Transplantation in HIV-Infected Recipients |
| Q38711186 | Pharmacokinetics of drugs in adult living donor liver transplant patients: regulatory factors and observations based on studies in animals and humans |
| Q42822380 | Population Pharmacokinetic Study of Cyclosporine Based on NONMEM in Chinese Liver Transplant Recipients |
| Q54231221 | Pre-emptive Treatment of HCV after Living Donor Liver Transplantation with Direct-Acting Antiviral Agents. |
| Q37919421 | Present state of immunosuppressive therapy in liver transplant recipients |
| Q42241628 | REFINE: a randomized trial comparing cyclosporine A and tacrolimus on fibrosis after liver transplantation for hepatitis C. |
| Q37771615 | Recipient-based approach to tailoring immunosuppression in liver transplantation |
| Q34067825 | Recurrent hepatitis C after liver transplant |
| Q38081919 | Recurrent hepatitis C virus infection post liver transplantation: impact of choice of calcineurin inhibitor. |
| Q36241697 | Response-Guided Therapy for Hepatitis C Virus Recurrence Based on Early Protocol Biopsy after Liver Transplantation |
| Q42776118 | Results of a two-center study comparing hepatic fibrosis progression in HCV-positive liver transplant patients receiving cyclosporine or tacrolimus |
| Q38083754 | Review article: the treatment of genotype 1 chronic hepatitis C virus infection in liver transplant candidates and recipients |
| Q36980754 | Risk factors for hepatitis C recurrence after liver transplantation |
| Q40113778 | Sensitivity of hepatitis C virus to cyclosporine A depends on nonstructural proteins NS5A and NS5B. |
| Q22305418 | Strategies to reduce hepatitis C virus recurrence after liver transplantation |
| Q34150039 | Tacrolimus-based versus cyclosporine-based immunosuppression in hepatitis C virus-infected patients after liver transplantation: a meta-analysis and systematic review |
| Q38057373 | The adverse pharmacology of calcineurin inhibitors and their impact on hepatitis C recurrence after liver transplantation: implications for clinical practice |
| Q34522556 | The impact of sirolimus on hepatitis C recurrence after liver transplantation |
| Q45325199 | The influence of immunosuppressants on direct-acting antiviral therapy is dependent on hepatitis C virus genotype |
| Q37937222 | The influence of immunosuppressive agents on BK virus risk following kidney transplantation, and implications for choice of regimen. |
| Q42991465 | The use of cyclosporine for recurrent hepatitis C after liver transplant: a randomized pilot study |
| Q36758660 | Therapeutic management of recurrent hepatitis C after liver transplantation |
| Q45358300 | Virus-drug interactions--molecular insight into immunosuppression and HCV. |
| Q80526260 | [Progress in immunosuppression] |
Search more.